60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape
22 January 2026
1 min read

60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

New York, January 22, 2026, 10:02 EST — Regular session

  • SXTP shares surged roughly 267% in early trading following news of a new distribution deal for its malaria-prevention drug
  • Starting April 2, Runway Health will provide online consultations and home delivery for ARAKODA prescriptions
  • The surge comes after a 1-for-4 reverse stock split that went into effect this week

Shares of 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) surged over 267% Thursday, hitting $7.34 by 9:57 a.m. EST. The stock had closed Wednesday at $2.00 and traded between $5.99 and $8.62 earlier today. 1

The announcement came after 60 Degrees unveiled a partnership with Runway Health, a travel medicine platform. Runway will provide physician-led online consultations and, when prescribed, arrange home delivery of ARAKODA (tafenoquine), the company’s malaria-prevention pill, for travelers heading abroad. 2

Why it matters now: ARAKODA stands as the company’s flagship commercial product. This deal slots it directly into a consumer telehealth platform aimed at travelers ahead of their trips. Telehealth—remote medical consultations online—broadens access to prescriptions that would normally demand an in-person pre-travel clinic appointment.

Traders are also watching the capital-structure reset closely. A recent filing revealed that 60 Degrees carried out a 1-for-4 reverse stock split, effective Jan. 20, merging every four shares into one to boost the stock price per share. 3

Volume spiked with the price, hitting roughly 115.9 million shares by 9:37 a.m. That’s a massive jump from the three-month average of around 168,000 shares, per Investing.com data. The company’s upcoming earnings report is scheduled for March 27. 4

The magnitude of the move highlights just how volatile micro-cap healthcare stocks can be when a headline drops and liquidity is scarce. Early jumps often attract short-term momentum traders, fueling sharper intraday swings.

But risks remain. The release didn’t reveal the financial details of the Runway deal, and the partnership won’t kick off right away. The commercial success depends on how many travelers move from online consults to actually filling prescriptions—and whether that demand holds steady beyond the initial buzz.

Investors are keeping an eye on whether SXTP can maintain its gains following the initial surge in volume, and if the company provides further details on expected uptake. The next key date is April 2, when 60 Degrees plans to kick off its partnership with Runway Health.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Apple stock price today: AAPL edges up as China discounts and Siri chatbot plans hit the tape
Previous Story

Apple stock price today: AAPL edges up as China discounts and Siri chatbot plans hit the tape

Intel stock slips after a 4-year high run as INTC earnings loom
Next Story

Intel stock slips after a 4-year high run as INTC earnings loom

Go toTop